Prognostic Models for HCC Based on Tumor Micronecrosis

Zhejiang University

Status: Enrolling

Conditions: Hepatocellular Carcinoma

Treatments: Other: observing whether HCC patients having tumor micronecrosis

Study type: Observational

Funder types: Other

Identifiers

NCT05837065

PMforHCC

Details and patient eligibility

About

The heterogeneity of hepatocellular carcinoma (HCC) leads to the unsatisfying predicting performance of current staging systems. HCC patients with pathological tumor micronecrosis have immunosuppressive microenvironment. We aimed to develop novel prognostic models by integrating micronecrosis to more precisely predict the survival of HCC patients after hepatectomy.

Enrollment: 765 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. pathologically diagnosed as HCC;
2. curative hepatectomy with R0 resection;
3. conserved liver function with Child Pugh class A or B

Exclusion criteria

1. with macrovascular invasion or extrahepatic metastasis;
2. receiving other anti-tumor treatments such as TACE or systemic drugs;
3. with other primary cancers;
4. incomplete follow-up data;
5. without sufficient formalin-fixed, paraffin-embedded (FFPE) specimens for micronecrosis evaluation

Trial design

765 participants in 2 patient groups

training cohort

Description:

HCC patients receiving curative hepatic resection

Treatment:

Other: observing whether HCC patients having tumor micronecrosis

validation cohort

Description:

HCC patients receiving curative hepatic resection

Treatment:

Other: observing whether HCC patients having tumor micronecrosis